Imaxio, which was created partly from a spin-off from the Medical Research Council and Cambridge University in the UK, raises extra funds.

Imaxio, a France-based vaccine and genomics business, raised €2.9m ($3.8m) from Pradeyrol Développement on Wednesday. Imaxio said the funds would be used for the clinical development of its vaccine-carrying protein platform, designed to improve the efficacy of vaccinations against human and animal diseased. It added the funds would also be used to also commercialising its…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.